A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

Trial Profile

A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2013

At a glance

  • Drugs Cenicriviroc (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Tobira Therapeutics
  • Most Recent Events

    • 07 Jun 2011 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Actual initiation date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 11 Feb 2011 Results published in the Journal of acquired immune deficiency syndromes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top